Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02744534 · ClinicalTrials.gov registry record · Phase 2
Targeted Fusion Biopsy of the Prostate
A Phase 2 study of Prostatic Neoplasms, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT02744534 is a Phase 2 study of Prostatic Neoplasms that has completed, run by Emory University. The registered enrollment target is 21 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT02744534, a Phase 2 study of Prostatic Neoplasms, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see if using Positron Emission Tomography (PET) scan and transrectal ultrasound (TRUS) guided biopsy together (creating a 3-dimensional ultrasound) will detect prostate cancer more accurately than the standard 2-dimensional approach which uses only the TRUS to guide the biopsy.
Conditions Studied
Interventions
- DRUG FACBC PET-CT Scan
- PROCEDURE Three-dimensional ultrasound-guided biopsy
- PROCEDURE Standard transrectal ultrasound (TRUS) guided biopsy
Study Locations (2)
Georgia
- Emory University Hospital - Atlanta
- Emory University Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02744534
The ClinicalTrials.gov registry entry for NCT02744534 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 3 interventions - of which FACBC PET-CT Scan is the first listed.
NCT02744534 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02744534 about?
NCT02744534 is a clinical study titled "Targeted Fusion Biopsy of the Prostate". The purpose of this study is to see if using Positron Emission Tomography (PET) scan and transrectal ultrasound (TRUS) guided biopsy together (creating a 3-dimensional ultrasound) will detect prostate cancer more accurately than the standard 2-dimensional approach which uses only the TRUS to guide t...
What is the current status of trial NCT02744534?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2015-11. Estimated completion is 2018-03-31.
What conditions does trial NCT02744534 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT02744534?
The interventions under investigation include: FACBC PET-CT Scan (DRUG), Three-dimensional ultrasound-guided biopsy (PROCEDURE), Standard transrectal ultrasound (TRUS) guided biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02744534?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02744534 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
RECRUITING · Phase 2
-
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
RECRUITING · Phase 2
-
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.